Corcept raises 2026 revenue guidance to $1.1-$1.2 billion on 32% Q2 sales gain
Corcept Therapeutics reported second-quarter 2026 revenue of $256.1 million, up 32% from $194.4 million a year earlier, and raised its 2026 revenue guidance to $1.1-$1.2 billion. Net income rose to $43.0 million from $35.1 million, though operating expenses increased to $214.8 million from $167.8 million on Lifyorli launch spending and Cushing's syndrome investments.
Key points
- Q2 2026 revenue of $256.1 million, including $47.6 million from Lifyorli in its first quarter of availability
- Diluted net income per share of $0.36, compared with $0.29 in Q2 2025
- Operating expenses rose to $214.8 million from $167.8 million, driven by Lifyorli launch and Cushing's investments
- Six-month net income was $11.2 million, down from $55.7 million a year earlier; the FDA decision on the Cushing's NDA is expected by December 17, 2026
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 29, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.